Literature DB >> 10947305

Household income losses associated with ischaemic heart disease for US employees.

J Herrin1, C B Cangialose, S J Boccuzzi, W S Weintraub, D J Ballard.   

Abstract

OBJECTIVE: To estimate the cost of lost work days due to ischaemic heart disease (IHD), and the cost of this reduced productivity using reduction in household income. DESIGN AND
SETTING: Using 2 years of nationally representative observational data, this study examined the effect on household income of IHD. This effect was estimated after accounting for unemployment, days lost to illness and other effects of illness on the income of workers aged 18 to 64 years. MAIN OUTCOME MEASURES AND
RESULTS: Previous measures of indirect costs of disease have typically not included the loss in productivity due to suboptimal work performance. Among workers in this age group, IHD was associated with a reduction of $US3013 in annual household income; this reduction was independent of occupational class, age, size of household and educational level. Such a reduction may be because of reduced on-the-job performance, employer perception of this, or unrelated lifestyle choices. It represents an estimated $US6.05 billion annual loss in productivity in 1992 dollars (or $US6.45 billion in 1996 dollars).
CONCLUSIONS: Estimates of the indirect costs of chronic disease that do not account fully for the lost income of employees may significantly underestimate the benefits to employers and society of treatment and prevention.

Entities:  

Mesh:

Year:  2000        PMID: 10947305     DOI: 10.2165/00019053-200017030-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  13 in total

1.  Productivity losses without absence: measurement validation and empirical evidence.

Authors:  W B Brouwer; M A Koopmanschap; F F Rutten
Journal:  Health Policy       Date:  1999-07       Impact factor: 2.980

2.  Health and labor market success: the role of various diseases.

Authors:  A Bartel; P Taubman
Journal:  Rev Econ Stat       Date:  1979-02

3.  Towards a new approach for estimating indirect costs of disease.

Authors:  M A Koopmanschap; B M van Ineveld
Journal:  Soc Sci Med       Date:  1992-05       Impact factor: 4.634

4.  The direct and indirect costs of cardiovascular disease in South Africa in 1991.

Authors:  J A Pestana; K Steyn; A Leiman; G M Hartzenberg
Journal:  S Afr Med J       Date:  1996-06

5.  Indirect cost in economic evaluation: the opportunity cost of unpaid inputs.

Authors:  J Posnett; S Jan
Journal:  Health Econ       Date:  1996 Jan-Feb       Impact factor: 3.046

Review 6.  The consequence of production loss or increased costs of production.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Med Care       Date:  1996-12       Impact factor: 2.983

7.  Combining National Health Interview Survey Datasets: issues and approaches.

Authors:  S L Botman; S S Jack
Journal:  Stat Med       Date:  1995 Mar 15-Apr 15       Impact factor: 2.373

8.  Ischaemic heart disease: disability and costs.

Authors:  S O Isacsson
Journal:  Qual Life Res       Date:  1994-12       Impact factor: 4.147

9.  A decline in earning losses associated with a community-based cardiovascular disease prevention project.

Authors:  T E Kottke; P Puska; R Feldman; J T Salonen; J Tuomilehto
Journal:  Med Care       Date:  1982-07       Impact factor: 2.983

10.  Labour productivity effects of prescribed medicines for chronically ill workers.

Authors:  J A Rizzo; T A Abbott; S Pashko
Journal:  Health Econ       Date:  1996 May-Jun       Impact factor: 3.046

View more
  2 in total

Review 1.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Disease-related income and economic productivity loss in New Zealand: A longitudinal analysis of linked individual-level data.

Authors:  Tony Blakely; Finn Sigglekow; Muhammad Irfan; Anja Mizdrak; Joseph Dieleman; Laxman Bablani; Philip Clarke; Nick Wilson
Journal:  PLoS Med       Date:  2021-11-30       Impact factor: 11.069

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.